About BONESUPPORT

News/Press Releases German
 

TWELVE-MONTH FOLLOW-UP OF CERAMENT™ WITH GENTAMICIN CONFIRMS SIGNIFICANT AND SUSTAINED ERADICATION OF CHRONIC INFECTION AND DEMONSTRATED FORMATION OF NEW BONE

24th September 2014

 

Lund, Sweden, (PRNEWSWIRE) September 24, 2014 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced new twelve-month follow-up data from an on-going clinical trial investigating the safety and efficacy of CERAMENT™|G in chronic bone infection and the completeness of bone healing after surgery. Results showed complete wound healing in all patients treated with CERAMENT™|G, and full bone remodeling of the void in 75% of patients at 6-months with evidence of ongoing bone remodeling in 80% of the remaining patients. The results were presented for the first time at the 33rd Annual Meeting of The European Bone & Joint Infection Society (EBJIS) and confirm significant and sustained eradication of chronic infection with formation of new bone.

CERAMENT™ WITH ANTIBIOTICS TO BE FEATURED PROMINENTLY AT 33RD ANNUAL MEETING OF THE EUROPEAN BONE & JOINT INFECTION SOCIETY (EBJIS)

9th September 2014

 

Lund, Sweden, (PRNEWSWIRE) September 9, 2014 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today that its platform technology CERAMENT™, will be prominently featured at the 33rd Annual Meeting of the European Bone & Joint Infection Society (EBJIS), September 11-13, in the Netherlands, including 12-month results of CERAMENT™|G from Nuffield Orthopaedic Centre in Oxford. CERAMENT™|G, which contains the antibiotic gentamicin, is the first injectable antibiotic eluting bone substitute indicated to promote and protect bone healing being jeopardized by infection offering surgeons a groundbreaking solution in the management of osteomyelitis.

CERAMENT™|G FEATURED IN DOCUMENTARY ‘THE ORTHOPAEDIC REVOLUTION: TREATING OSTEOMYELITIS’

5th August 2014

 

Lund, Sweden, (PRNEWSWIRE) August 5, 2014 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that CERAMENT™|G is a prominent feature in a new documentary, ‘The Orthopaedic Revolution: Treating Osteomyelitis’, which recently aired on the National Health Channel. The documentary features Martin McNally, Lead Surgeon and Andrew Woodhouse, Lead Infectious Disease Consultant at the Bone Infection Unit of the Nuffield Orthopaedic Centre in Oxford, and explores a multidisciplinary approach to patient care, highlighting the risk of antibiotic resistance and the impact of new innovations such as the local delivery of antibiotics directly into the bone. The program further discusses clinical experience with CERAMENT™|G, the first injectable antibiotic eluting bone substitute indicated to promote and protect bone healing being jeopardized by infection.

BONESUPPORT AB ANNOUNCES CHUV IN SWITZERLAND INITIATES STUDY OF CERAMENT™|G FOR ONE-STAGE SURGICAL REVISION OF BONE INFECTIONS

19th June 2014

 

Lund, Sweden, (PRNEWSWIRE) June 19, 2014 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced the initiation of a CERAMENT™|G Bone Healing study by the CHUV (Centre Hospitalier Universitaire Vaudois), in Lausanne, Switzerland. The CERAMENT™|G Bone Healing study is a prospective, controlled, cohort study investigating the absorption and bone in-growth of CERAMENT™|G in one-stage surgical revisions of bone infections. Dr. Olivier Borens, head of the septic unit at the CHUV, is principal clinical investigator for the study, which will follow patients for 12 months post surgery.